These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 19643213)

  • 1. Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis.
    Gaston JS; Inman RD; Ryan ET; Venkatesan MM; Barry EM; Hale TL; Bourgeois AL; Walker RI
    Vaccine; 2009 Sep; 27(40):5432-4. PubMed ID: 19643213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress towards development of a Shigella vaccine.
    Camacho AI; Irache JM; Gamazo C
    Expert Rev Vaccines; 2013 Jan; 12(1):43-55. PubMed ID: 23256738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shigellosis.
    Niyogi SK
    J Microbiol; 2005 Apr; 43(2):133-43. PubMed ID: 15880088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shigellosis: the current status of vaccine development.
    Kweon MN
    Curr Opin Infect Dis; 2008 Jun; 21(3):313-8. PubMed ID: 18448978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries.
    Walker RI
    Vaccine; 2005 May; 23(26):3369-85. PubMed ID: 15837361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.
    Levine MM; Kotloff KL; Barry EM; Pasetti MF; Sztein MB
    Nat Rev Microbiol; 2007 Jul; 5(7):540-53. PubMed ID: 17558427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-B27/microbial mimicry: an in vivo analysis.
    Kapasi K; Chui B; Inman RD
    Immunology; 1992 Nov; 77(3):456-61. PubMed ID: 1478690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live-attenuated Shigella vaccines.
    Venkatesan MM; Ranallo RT
    Expert Rev Vaccines; 2006 Oct; 5(5):669-86. PubMed ID: 17181440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reaction of anti-HLA-B monoclonal antibodies with envelope proteins of Shigella species. Evidence for molecular mimicry in the spondyloarthropathies.
    Raybourne RB; Bunning VK; Williams KM
    J Immunol; 1988 May; 140(10):3489-95. PubMed ID: 3283236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Shigella flexneri serotype Y vaccine candidate SFL124 originated from a serotype 2a background.
    Roberts F; Jennison AV; Verma NK
    FEMS Immunol Med Microbiol; 2005 Aug; 45(2):285-9. PubMed ID: 15963704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivated and subunit vaccines to prevent shigellosis.
    Kaminski RW; Oaks EV
    Expert Rev Vaccines; 2009 Dec; 8(12):1693-704. PubMed ID: 19943764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies.
    Camacho AI; Souza-Rebouças J; Irache JM; Gamazo C
    Methods; 2013 May; 60(3):264-8. PubMed ID: 23046911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery.
    Phalipon A; Sansonetti P
    Biologicals; 1995 Jun; 23(2):125-34. PubMed ID: 7546655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perceptions of Shigella and of Shigella vaccine among rural Chinese: compatibility with Western models of behavioral change.
    Youlong G; Stanton BF; Von Seidlen L; Xueshan F; Nyamette A
    Southeast Asian J Trop Med Public Health; 2004 Mar; 35(1):97-108. PubMed ID: 15272751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole genome analysis to detect potential vaccine-induced changes on Shigella sonnei genome.
    Behar A; Fookes MC; Goren S; Thomson NR; Cohen D
    Vaccine; 2015 Jun; 33(26):2978-83. PubMed ID: 25936664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of self-reported joint symptoms following infection with different enteric pathogens: effect of HLA-B27.
    Schiellerup P; Krogfelt KA; Locht H
    J Rheumatol; 2008 Mar; 35(3):480-7. PubMed ID: 18203313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.
    Jennison AV; Roberts F; Verma NK
    FEMS Immunol Med Microbiol; 2006 Apr; 46(3):444-51. PubMed ID: 16553820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility and HLA-B27 in post-dysenteric arthropathies.
    van Bohemen CG; Lionarons RJ; van Bodegom P; Dinant HJ; Landheer JE; Nabbe AJ; Grumet FC; Zanen HC
    Immunology; 1985 Oct; 56(2):377-9. PubMed ID: 3902627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reactive arthritis in children].
    Piussan C; Pautard-Muchemble B; Pautard JC; Lenaerts C; Boudailliez B; Risbourg B
    Sem Hop; 1984 Jan; 60(1):52-62. PubMed ID: 6320436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.
    Kim JO; Rho S; Kim SH; Kim H; Song HJ; Kim EJ; Kim RY; Kim EH; Sinha A; Dey A; Yang JS; Song MK; Nandy RK; Czerkinsky C; Kim DW
    Clin Vaccine Immunol; 2015 Apr; 22(4):381-8. PubMed ID: 25651919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.